ANIP — ANI Pharmaceuticals, Inc.

Is ANIP overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Drug Manufacturers - Specialty & Generic

Neutral As of August 19, 2026

ANI Pharmaceuticals, Inc. (ANIP) currently reads Neutral on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Drug Manufacturers - Specialty & Generic) last closed at $78.02. The rating moved from Oversold to Neutral on August 18, 2026.

AI analysis

ANI Pharmaceuticals, Inc. (ANIP) is positioned to capture outsourcing demand in specialty injectables and CDMO services, with favorable secular tailwinds from biologics and synthetic-biology activity. Operational execution and a solid product-mix underpin near-term revenue visibility, while a reasonable balance sheet allows for capacity investments and potential M&A. Key near-term catalysts include contract wins, margin leverage from higher utilization, and continued demand from biologics/GLP-1 related workflows. Material risks include customer concentration, regulatory/manufacturing interruptions, and competitive pricing pressure which could compress margins or slow growth.

Key factors

  • Exposure to CDMO/specialty pharmaceutical manufacturing trends which benefit from increased outsourcing and the GLP-1/biologics supplier supercycle
  • Diversified product mix across sterile injectables, specialty generics and contract manufacturing which supports revenue stability and margin expansion
  • Recent operational execution showing steady order flow and defense against headline-driven volatility in the market window provided
  • Attractive M&A backdrop and elevated strategic acquirer multiples in pharma/biotech that can support valuation upside and strategic options
  • Reasonable balance-sheet positioning and cash-flow generation relative to peers (supports capex for capacity and potential tuck‑ins)
  • Selective secular demand drivers (diagnostics/biologics) and potential contract wins that can drive near-term revenue beats

Risks

  • Customer concentration risk: loss or renegotiation of a major contract could meaningfully impact revenue
  • Regulatory and manufacturing risks: product recalls, quality-control issues or FDA actions could interrupt production and revenues
  • Pricing pressure and payer dynamics could compress margins for some product lines over time
  • Supply-chain constraints or raw-material cost inflation could affect gross margins and delivery timelines
  • Competitive risk from larger CDMOs or integrated pharma players expanding into specialty injectables
  • Macro sensitivity: slower pharma capex or softness in biotech funding could reduce outsourcing demand

See today's live rating, score and targets

Members see the live hourly rating for ANIP — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.